BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Price Performance

Shares of BLRX opened at $0.26 on Friday. BioLineRx has a fifty-two week low of $0.19 and a fifty-two week high of $1.58. The firm’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.53. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market cap of $20.43 million, a P/E ratio of -1.16 and a beta of 1.39.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CVI Holdings LLC purchased a new stake in shares of BioLineRx in the second quarter valued at $462,000. Atria Investments Inc boosted its holdings in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new position in shares of BioLineRx in the 2nd quarter valued at about $70,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.